OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $348,000.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $1.74 per share, for a total transaction of $348,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,501,448 shares in the company, valued at $371,492,519.52. The trade was a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The shares were purchased at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Trading Down 1.1 %

Shares of OPK stock opened at $1.79 on Wednesday. The firm has a market cap of $1.20 billion, a P/E ratio of -9.42 and a beta of 1.70. OPKO Health, Inc. has a 1-year low of $0.86 and a 1-year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm’s 50-day simple moving average is $1.63 and its 200-day simple moving average is $1.57.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Rubric Capital Management LP raised its holdings in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. Millennium Management LLC raised its holdings in OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after buying an additional 2,112,382 shares during the period. Northern Trust Corp raised its holdings in OPKO Health by 4.7% in the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock valued at $5,436,000 after buying an additional 164,847 shares during the period. Lazard Asset Management LLC grew its position in OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after acquiring an additional 949,671 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on OPK. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.